Polaryx Therapeutics, Inc. (PLYX): Cash & Equivalents
$5.14M
As of 2025-12-31
$11.54M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.14M | +11.3% | 2026-03-24, Balance as of period end |
| 2024-12-31 | $4.62M | n/a | 2026-03-24, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | 2025-12-31 | $5.14M | +11.3% |
| Petros Pharmaceuticals, Inc. (PTPI) | 2025-12-31 | $5.14M | +198.9% |
| Azitra, Inc. (AZTR) | 2025-12-31 | $2.07M | -54.6% |
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | 2025-12-31 | $1.51M | -9.0% |
| AEON Biopharma, Inc. (AEON) | 2025-12-31 | $3.01M | n/m |
| CDT Equity Inc. (CDT) | 2025-12-31 | $1.51M | +172.4% |
| Ernexa Therapeutics Inc. (ERNA) | 2024-12-31 | $1.73M | -77.2% |
| Cadrenal Therapeutics, Inc. (CVKD) | 2025-12-31 | $4.01M | -60.0% |
| Greenwich LifeSciences, Inc. (GLSI) | 2025-12-31 | $6.18M | +51.0% |
Compare PLYX, PTPI, AZTR, SXTP side by side · Screen every company in Pharmaceutical Preparations ↗